NASDAQ$DH
Definitive Healthcare Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Definitive Healthcare's financial performance underscored commitment to operational efficiency and profitability.
Definitive Healthcare reported a 5% year-over-year increase in revenue, reaching $63.7 million for the second quarter of fiscal year 2024. The company's adjusted EBITDA increased by 21% to $20.9 million, representing 33% of revenue. However, the company experienced a net loss of $(306.2) million, which included goodwill impairment charges of $363.6 million.
- Revenue was $63.7 million, a 5% increase compared to $61.0 million in Q2 2023.
- Net loss, including goodwill impairment charges of $363.6 million, was $(306.2) million, a 2,538% increase compared to $(11.6) million in Q2 2023.
- Adjusted Net Income was $14.2 million, compared to $12.4 million in Q2 2023.
- Adjusted EBITDA was $20.9 million, up 21% from Q2 2023.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$63.7M
Forward guidance
The Company is issuing the following financial guidance. Third Quarter 2024: Revenue is expected to be in the range of $61.0 – $62.5 million. Adjusted Operating Income is expected to be in the range of $16.0 – $17.5 million. Adjusted EBITDA is expected to be in the range of $17.5 – $19.0 million, and 28-31% adjusted EBITDA margin. Adjusted Net Income is expected to be $12.0 – $13.0 million. Adjusted Net Income Per Diluted Share is expected to be $0.07 – $0.08 per share on approximately 156.5 million weighted-average shares outstanding. Full Year 2024: Revenue is expected to be in the range of $247 – $251 million. Adjusted Operating Income is expected to be in the range of $67 – $71 million. Adjusted EBITDA is expected to be in the range of $74 – $77 million, for a full-year adjusted EBITDA margin of 30-31%. Adjusted Net Income is expected to be $50 – $53 million. Adjusted Net Income Per Diluted Share is expected to be $0.32 – $0.34 per share on approximately 156.8 million weighted-average shares outstanding.
Tailwinds
- Revenue is expected to be in the range of $61.0 – $62.5 million for Q3 2024.
- Adjusted Operating Income is expected to be in the range of $16.0 – $17.5 million for Q3 2024.
- Adjusted EBITDA is expected to be in the range of $17.5 – $19.0 million for Q3 2024.
- Adjusted EBITDA margin of 28-31% is expected for Q3 2024.
- Adjusted Net Income is expected to be $12.0 – $13.0 million for Q3 2024.
Headwinds
- The company does not provide a quantitative reconciliation of the forward-looking non-GAAP financial measures included in this press release to the most directly comparable GAAP measures due to the high variability and difficulty to predict certain items excluded from these non-GAAP financial measures.
- Variability of excluded items may have a significant, and potentially unpredictable, impact on future GAAP financial results.
- Inability to realize expected business or financial benefits from acquisitions and the risk that our acquisitions or investments could prove difficult to integrate, disrupt our business, dilute stockholder value and adversely affect our business, financial condition and results of operations.
- Our inability to achieve the anticipated cost savings, operating efficiencies or other benefits of our internal restructuring activities; global geopolitical tension and difficult macroeconomic conditions.
- Actual or potential changes in international, national, regional and local economic, business and financial conditions, including recessions, inflation, high interest rates, volatility in the capital markets and related market uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2024
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro